Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study-Reference-Cited by-同舟云学术

Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study

Published:2024-06 Issue:6 Volume:11 Page:e406-e414
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Dupuis Jehan,Bachy Emmanuel,Morschhauser Franck,Cartron Guillaume,Fukuhara Noriko,Daguindau Nicolas,Casasnovas René-Olivier,Snauwaert Sylvia,Gressin Remy,Fox Christopher P,d’Amore Francesco Annibale,Staber Philipp B,Tournilhac Olivier,Bouabdallah Krimo,Thieblemont Catherine,André Marc,Rai Shinya,Ennishi Daisuke,Gkasiamis Argyrios,Nishio Mitsufumi,Fornecker Luc-Matthieu,Delfau-Larue Marie-Helene,Sako Nouhoum,Mule Sebastien,de Leval Laurence,Gaulard Philippe,Tsukasaki Kunihiro,Lemonnier François

Funder

Bristol-Myers Squibb Company

Publisher

Elsevier BV

Reference30 articles.

1. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes;Vose;J Clin Oncol,2008

2. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors;Mak;J Clin Oncol,2013

3. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy;Coiffier;J Clin Oncol,2012

4. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) Study;O'Connor;J Clin Oncol,2015

5. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study;O'Connor;J Clin Oncol,2011

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted agents plus CHOP compared with CHOP as the first-line treatment for newly diagnosed patients with peripheral T-cell lymphoma (GUIDANCE-03): an open-label, multicentre phase 2 clinical trial;The Lancet Regional Health - Western Pacific;2024-09

2. Optimizing Frontline Treatment for PTCL;Clinical Lymphoma Myeloma and Leukemia;2024-09